Amarin reported 91.05 in PE Price to Earnings for its fiscal quarter ending in June of 2023.





Pe Change Date
AbbVie 23.96 0.93 Jun/2026
Alnylam Pharmaceuticals 75.64 4.4 Jun/2026
Amarin 91.05 88.3 Jun/2023
AstraZeneca 25.34 4.25 Jun/2026
BioCryst Pharmaceuticals 6.84 0.78 Jun/2026
GlaxoSmithKline 10.63 4.24 Jun/2026
Halozyme Therapeutics 11.35 11.8 Mar/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Neurocrine Biosciences 22.1 5.99 Jun/2026
Novartis 22.41 2.24 Jun/2026